Citation Impact
Citing Papers
Impact of Positron Emission Tomography/Computed Tomography and Positron Emission Tomography (PET) Alone on Expected Management of Patients With Cancer: Initial Results From the National Oncologic PET Registry
2008
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
2007 StandoutScience
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
2011 Standout
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
2013 Standout
Colorectal cancer statistics, 2020
2020 Standout
Metastasis: from dissemination to organ-specific colonization
2009 Standout
Early glandular neoplasia of the lung
2000
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
Long COVID: major findings, mechanisms and recommendations
2023 Standout
EGFR Antagonists in Cancer Treatment
2008 Standout
A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer
2006
Determining cell type abundance and expression from bulk tissues with digital cytometry
2019 Standout
Acromegaly
2006 Standout
Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial
2009
Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449
2009 Standout
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
2008 Standout
Breast cancer
2016 Standout
The tor pathway: a target for cancer therapy
2004 Standout
Atypical Adenomatous Hyperplasia of the Lung: A Probable Forerunner in the Development of Adenocarcinoma of the Lung
2001
HIF-1 and tumor progression: pathophysiology and therapeutics
2002 StandoutNobel
Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial
2016
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
2009 Standout
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
Outcomes of Hypofractionated High-Dose Radiotherapy in Poor-Risk Patients with “Ultracentral” Non–Small Cell Lung Cancer
2016
Epidermal growth factor receptor mutations in lung cancer
2007 Standout
Lung Cancer
2008 Standout
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy
2006
Molecular defects in the pathogenesis of pituitary tumours
2003
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 Standout
Expression of angiogenesis‐related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis
2001 StandoutNobel
Induction chemotherapy and radiotherapy in locally advanced non–small cell lung cancer
2004
Taxanes in the treatment of breast cancer: Have we better defined their role in older patients? A position paper from a SIOG Task Force
2015
The biology and function of fibroblasts in cancer
2016 Standout
Cellular and molecular pathobiology of pulmonary arterial hypertension
2004 Standout
New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer
2018 Standout
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
2010 Standout
Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer
2015 Standout
Angiogenesis in health and disease
2003 Standout
Recommendations for the Management of Subsolid Pulmonary Nodules Detected at CT: A Statement from the Fleischner Society
2012
Identification of Bronchioalveolar Stem Cells in Normal Lung and Lung Cancer
2005 Standout
Cell-free nucleic acids as biomarkers in cancer patients
2011 Standout
A review of the benefit–risk profile of gefitinib in Asian patients with advanced non‐small‐cell lung cancer
2006
EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer
2006
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2017 Standout
Gefitinib — a novel targeted approach to treating cancer
2004
Chemotherapy-Induced Nausea and Vomiting
2008 Standout
Malignant Gliomas in Adults
2008 Standout
Hindlimb Suspension and SPE-Like Radiation Impairs Clearance of Bacterial Infections
2014 StandoutNobel
Phenotype molding of stromal cells in the lung tumor microenvironment
2018
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
2023 Standout
EMT: 2016
2016 Standout
Microtubule-binding agents: a dynamic field of cancer therapeutics
2010 Standout
Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial
2016
YAP inhibits squamous transdifferentiation of Lkb1-deficient lung adenocarcinoma through ZEB2-dependent DNp63 repression
2014
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
2017
Paul Ehrlich's magic bullet concept: 100 years of progress
2008 Standout
Phenotypic and functional heterogeneity of cancer-associated fibroblast within the tumor microenvironment
2015
Methods for Staging Non-small Cell Lung Cancer
2013
Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)
2008
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
Epithelial mesenchymal transition (EMT) and non-small cell lung cancer (NSCLC): a mutual association with airway disease
2017
Molecular Regulation of Vascular Smooth Muscle Cell Differentiation in Development and Disease
2004 Standout
NF-κB, inflammation, immunity and cancer: coming of age
2018 Standout
Chronic obstructive pulmonary disease and interstitial lung disease in patients with lung cancer
2009
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America
2014 Standout
Head and Neck Cancer
2020 Standout
Prevention and Treatment of Cancer-Related Infections
2012
CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010
2013 Standout
Review of Phase II Trial Designs Used in Studies of Molecular Targeted Agents: Outcomes and Predictors of Success in Phase III
2008
Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America
2011 Standout
Phase III Study of Docetaxel Compared With Vinorelbine in Elderly Patients With Advanced Non–Small-Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904)
2006
Tumor Budding: The Name is EMT. Partial EMT.
2016
Specific EGFR Mutations Predict Treatment Outcome of Stage IIIB/IV Patients With Chemotherapy-Naive Non–Small-Cell Lung Cancer Receiving First-Line Gefitinib Monotherapy
2008
Prospective Phase II Study of Gefitinib for Chemotherapy-Naïve Patients With Advanced Non–Small-Cell Lung Cancer With Epidermal Growth Factor Receptor Gene Mutations
2006
Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Non–Small-Cell Lung Cancer
2007
Antimicrobial Prophylaxis and Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology Clinical Practice Guideline
2013
Chemoradiotherapy in Malignant Glioma: Standard of Care and Future Directions
2007
Cancer Genome Landscapes
2013 StandoutScience
Gefitinib as a First-Line Therapy of Advanced or Metastatic Adenocarcinoma of the Lung in Never-Smokers
2005
Treatment of Advanced Non–Small-Cell Lung Cancer in the Elderly: Results of an International Expert Panel
2005
Expression of eukaryotic initiation factor 4E in atypical adenomatous hyperplasia and adenocarcinoma of the human peripheral lung.
2002
Microsatellite Instability of Endothelial Cell Growth and Apoptosis Genes Within Plexiform Lesions in Primary Pulmonary Hypertension
2001
Works of Seiji Niho being referenced
Podoplanin-Positive Cancer-Associated Fibroblasts in the Tumor Microenvironment Induce Primary Resistance to EGFR-TKIs in Lung Adenocarcinoma with EGFR Mutation
2014
Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and EGFR-Activating Mutations
2018
Interstitial Shadow on Chest CT is Associated with the Onset of Interstitial Lung Disease Caused by Chemotherapeutic Drugs
2006
Monoclonality of Atypical Adenomatous Hyperplasia of the Lung
1999
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
2017
Characterization of the immunophenotype of the tumor budding and its prognostic implications in squamous cell carcinoma of the lung
2011
Combined evaluation of preoperative FDG uptake on PET, ground-glass opacity area on CT, and serum CEA level: identification of both low and high risk of recurrence in patients with resected T1 lung adenocarcinoma
2008
Randomized Trial of Oral Versus Intravenous Antibiotics in Low-risk Febrile Neutropenic Patients with Lung Cancer
2004
CD200-positive cancer associated fibroblasts augment the sensitivity of Epidermal Growth Factor Receptor mutation-positive lung adenocarcinomas to EGFR Tyrosine kinase inhibitors
2017
Factors influencing the concordance of histological subtype diagnosis from biopsy and resected specimens of lung adenocarcinoma
2016
Comparison of the expression levels of molecular markers among the peripheral area and central area of primary tumor and metastatic lymph node tumor in patients with squamous cell carcinoma of the lung
2015
Efficacy of droperidol in the prevention of cisplatin-induced delayed emesis
2004
Pitfalls in lymph node staging with positron emission tomography in non-small cell lung cancer patients
2004
Risk factors associated with fatal pulmonary hemorrhage in locally advanced non-small cell lung cancer treated with chemoradiotherapy
2012
A phase II study of cisplatin and docetaxel administered as three consecutive weekly infusions for advanced non-small-cell lung cancer in elderly patients
2003
Monoclonality of both pale cells and cuboidal cells of sclerosing hemangioma of the lung.
1998
Podoplanin-expressing cancer-associated fibroblasts inhibit small cell lung cancer growth
2015
Clonal Analysis of Adenosquamous Carcinoma of the Lung
1999
Clinicopathological characteristics of EGFR mutated adenosquamous carcinoma of the lung
2013
First-line single agent of gefitinib in patients (pts) with advanced non-small cell lung cancer (NSCLC): A phase II study
2004
Attenuation of Antibody Titers from 3 to 6 Months after the Second Dose of the BNT162b2 Vaccine Depends on Sex, with Age and Smoking Risk Factors for Lower Antibody Titers at 6 Months
2021
Association of multiple pulmonary metastases with response to gefitinib in patients with non-small cell lung cancer
2004
779 A pilot study of hyperfractionated accelerated radiotherapy (HART) following induction cisplatin and vinorelbine for stage III non-small cell lung cancer (NSCLC)
2003
Comparison of Pharmacokinetics and Pharmacodynamics of Docetaxel and Cisplatin in Elderly and Non-Elderly Patients: Why Is Toxicity Increased in Elderly Patients?
2004
A phase II open-label single-arm study of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer (NSCLC): Luret study.
2016
First-Line Single Agent Treatment With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer: A Phase II Study
2005
Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial.
2017
Results of a randomized phase III study to compare the overall survival of gefitinib (IRESSA) versus docetaxel in Japanese patients with non-small cell lung cancer who failed one or two chemotherapy regimens
2007
First-line single agent of gefitinib in patients (pts) with advanced non-small cell lung cancer (NSCLC): A phase II study
2004